Nivolumab was approved for the treatment of platinum-resistant metastatic or unresectable urothelial carcinoma (mUC) on the basis of results from the CheckMate 275 trial. Identification of predictive biomarkers that could enrich for response to nivolumab treatment is of interest in this setting. Galsky and colleagues reported efficacy and safety from CheckMate 275 with minimum follow-up of 33.7 months, and exploratory biomarker analyses of tumor mutational burden (TMB), PD-L1, and previously identified mutational signatures. These results support the durable antitumor activity of nivolumab and suggest that TMB, particularly combined with PD-L1 expression, may enrich for better response to nivolumab in mUC.

Platinum-based chemotherapies or treatment with PARP inhibitors have demonstrated promising activity in patients with metastatic pancreatic cancer (PDAC) who harbor pathogenic germline or somatic mutations in the homologous recombination, DNA damage response and repair (HR-DDR) genes, BRCA1/2, or PALB2. Here, Pishvaian and colleagues assess the safety and efficacy of the...

You do not currently have access to this content.